Madrigal Pharmaceuticals (MDGL) Debt to Equity (2022 - 2025)
Historic Debt to Equity for Madrigal Pharmaceuticals (MDGL) over the last 10 years, with Q3 2025 value amounting to $0.54.
- Madrigal Pharmaceuticals' Debt to Equity rose 26039.1% to $0.54 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.54, marking a year-over-year increase of 26039.1%. This contributed to the annual value of $0.16 for FY2024, which is 4529.76% down from last year.
- Per Madrigal Pharmaceuticals' latest filing, its Debt to Equity stood at $0.54 for Q3 2025, which was up 26039.1% from $0.17 recorded in Q2 2025.
- In the past 5 years, Madrigal Pharmaceuticals' Debt to Equity registered a high of $5.16 during Q3 2023, and its lowest value of $0.14 during Q2 2024.
- Its 4-year average for Debt to Equity is $0.99, with a median of $0.27 in 2022.
- As far as peak fluctuations go, Madrigal Pharmaceuticals' Debt to Equity tumbled by 9707.82% in 2024, and later surged by 26039.1% in 2025.
- Over the past 4 years, Madrigal Pharmaceuticals' Debt to Equity (Quarter) stood at $0.25 in 2022, then rose by 14.1% to $0.28 in 2023, then plummeted by 45.3% to $0.16 in 2024, then skyrocketed by 248.4% to $0.54 in 2025.
- Its Debt to Equity was $0.54 in Q3 2025, compared to $0.17 in Q2 2025 and $0.17 in Q1 2025.